New drug combo targets Hard-to-Treat nasopharyngeal cancer
NCT ID NCT04825990
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether combining pembrolizumab (an immunotherapy) with olaparib (a PARP inhibitor) can shrink tumors in people with nasopharyngeal cancer that has become resistant to platinum-based chemotherapy. The study plans to enroll 30 adults whose cancer has progressed within 6 months of platinum treatment. Participants receive both drugs until the cancer worsens, side effects become too severe, or up to 2 years of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab and olaparib
What this could lead to
If it works, this combination could offer a new treatment option for people with nasopharyngeal cancer that has stopped responding to platinum-based chemotherapy.
What could go wrong
This is a small, early-phase trial with only 30 participants. The combination may not improve outcomes and could cause significant side effects from the immune system and DNA repair inhibition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asst Degli Spedali Civili Di Brescia
Brescia, Brescia, 25123, Italy